Jing Su

503 total citations
17 papers, 344 citations indexed

About

Jing Su is a scholar working on Cancer Research, Molecular Biology and Surgery. According to data from OpenAlex, Jing Su has authored 17 papers receiving a total of 344 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Cancer Research, 8 papers in Molecular Biology and 2 papers in Surgery. Recurrent topics in Jing Su's work include Cancer-related molecular mechanisms research (7 papers), MicroRNA in disease regulation (5 papers) and RNA modifications and cancer (4 papers). Jing Su is often cited by papers focused on Cancer-related molecular mechanisms research (7 papers), MicroRNA in disease regulation (5 papers) and RNA modifications and cancer (4 papers). Jing Su collaborates with scholars based in China and United States. Jing Su's co-authors include Mengquan Li, Keke Miao, Yanwei Zhang, Jianfang Hu, Yang Li, Yanqing Li, Ying Ji, Guoxin Zhang, Hui Yang and Yan Jiao and has published in prestigious journals such as The Journal of Immunology, Neuroscience and Frontiers in Immunology.

In The Last Decade

Jing Su

16 papers receiving 339 citations

Peers

Jing Su
Jun-Shuang Jia China
Ting‐Miao Wu China
Reem K. Shahin Egypt
Shaolin Nie China
Zehui Hou China
Jian Shi China
Tait Huso United States
Daniel E. Foxler United Kingdom
Chen Lin China
Haojie Dong China
Jun-Shuang Jia China
Jing Su
Citations per year, relative to Jing Su Jing Su (= 1×) peers Jun-Shuang Jia

Countries citing papers authored by Jing Su

Since Specialization
Citations

This map shows the geographic impact of Jing Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jing Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jing Su more than expected).

Fields of papers citing papers by Jing Su

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jing Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jing Su. The network helps show where Jing Su may publish in the future.

Co-authorship network of co-authors of Jing Su

This figure shows the co-authorship network connecting the top 25 collaborators of Jing Su. A scholar is included among the top collaborators of Jing Su based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jing Su. Jing Su is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Lu, Junjie, et al.. (2025). TEAD1 KNOCKDOWN IMPEDES THE INFLAMMATION AND FERROPTOSIS BY MEDIATING MMP3 IN CEREBRAL ISCHEMIA REPERFUSION. Shock. 64(2). 205–212. 1 indexed citations
2.
Huang, Qiang, Yun Yang, Hongwei Ma, et al.. (2025). Disturbed neurovascular coupling of limbic system in obstructive sleep apnea patients with mild cognitive impairment: A combined fMRI and ASL study. Neuroscience. 581. 104–113. 1 indexed citations
3.
Gao, Ling, Jingxin Zhou, Wei Chen, et al.. (2024). Activation of non-classical Wnt signaling pathway effectively enhances HLA-A presentation in acute myeloid leukemia. Frontiers in Oncology. 14. 1336106–1336106.
4.
5.
Su, Jing, et al.. (2023). Functions and mechanisms of lactylation in carcinogenesis and immunosuppression. Frontiers in Immunology. 14. 1253064–1253064. 34 indexed citations
6.
Wang, Jian, et al.. (2023). LINC00365 functions as a tumor suppressor by inhibiting HIF-1α-mediated glucose metabolism reprogramming in breast cancer. Experimental Cell Research. 425(1). 113514–113514. 13 indexed citations
7.
8.
Ding, Xiaoyuan, Jing Su, Xiaohong Chen, et al.. (2022). Application of synergistic β-lactamase inhibitors and antibiotics in the treatment of wounds infected by superbugs. Arabian Journal of Chemistry. 15(7). 103936–103936. 4 indexed citations
9.
Li, Mengquan, et al.. (2019). Dual-Targeting of miR-124-3p and ABCC4 Promotes Sensitivity to Adriamycin in Breast Cancer Cells. Genetic Testing and Molecular Biomarkers. 23(3). 156–165. 29 indexed citations
10.
Li, Yanqing, et al.. (2019). <p>High miR-454-3p expression predicts poor prognosis in hepatocellular carcinoma</p>. Cancer Management and Research. Volume 11. 2795–2802. 41 indexed citations
11.
Su, Jing, et al.. (2019). Silencing of the long non-coding RNA RHPN1-AS1 suppresses the epithelial-to-mesenchymal transition and inhibits breast cancer progression.. PubMed. 11(6). 3505–3517. 17 indexed citations
12.
Su, Jing, et al.. (2018). MiR‐134‐5p attenuates neuropathic pain progression through targeting Twist1. Journal of Cellular Biochemistry. 120(2). 1694–1701. 18 indexed citations
13.
Zhang, Rong, Jing Su, Hui Yang, et al.. (2016). HPV E6/p53 mediated down-regulation of miR-34a inhibits Warburg effect through targeting LDHA in cervical cancer.. PubMed. 6(2). 312–20. 75 indexed citations
14.
Wen, Qian, Chaoying Zhou, Wenjing Xiong, et al.. (2016). MiR-381-3p Regulates the Antigen-Presenting Capability of Dendritic Cells and Represses Antituberculosis Cellular Immune Responses by Targeting CD1c. The Journal of Immunology. 197(2). 580–589. 18 indexed citations
15.
Su, Jing, et al.. (2015). [Value of FOXP3 Tregs predicting the effectiveness of neoadjuvant chemotherapy in patients with breast cancer].. PubMed. 95(8). 595–7. 1 indexed citations
16.
Zhou, Xiaoying, Jing Su, Li Zhu, & Guoxin Zhang. (2014). Helicobacter pylori Modulates Cisplatin Sensitivity in Gastric Cancer by Down‐Regulating miR‐141 Expression. Helicobacter. 19(3). 174–181. 27 indexed citations
17.
Yan, Guijun, Fei Yu, Bin Wang, et al.. (2013). MicroRNA miR-302 inhibits the tumorigenicity of endometrial cancer cells by suppression of Cyclin D1 and CDK1. Cancer Letters. 345(1). 39–47. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jun-Shuang Jia Breakdown of academic impact, for papers by Ting‐Miao Wu Breakdown of academic impact, for papers by Reem K. Shahin Breakdown of academic impact, for papers by Shaolin Nie Breakdown of academic impact, for papers by Zehui Hou Breakdown of academic impact, for papers by Jian Shi Breakdown of academic impact, for papers by Tait Huso Breakdown of academic impact, for papers by Daniel E. Foxler Breakdown of academic impact, for papers by Chen Lin Breakdown of academic impact, for papers by Haojie Dong
Rankless by CCL
2026